item: #1 of 79 id: cord-000522-d498qj2b author: Vincent, Jean-Louis title: Reducing mortality in sepsis: new directions date: 2002-12-05 words: 8718 flesch: 43 summary: Interestingly, this decrease was apparent even before the five interventions discussed in the present article were published, reflecting improvements in the general supportive care of sepsis patients. Generalists have been taught to recognize the signs Sepsis patients often come 'second hand' from a and symptoms of AMI; initial treatment is usually specialist who may not be appropriately trained to provided by emergency physicians, who are trained diagnose, manage, and refer patients with sepsis to treat these patients Mortality prior to hospital discharge in patients receiving a tidal volume of 6 and 12 ml/kg ideal body weight. keywords: alfa; care; drotrecogin; group; icu; interventions; mortality; patients; protein; sepsis; shock; study; therapy; treatment; trial cache: cord-000522-d498qj2b.txt plain text: cord-000522-d498qj2b.txt item: #2 of 79 id: cord-001050-lq9tp20z author: Khanafer, Nagham title: Severe leukopenia in Staphylococcus aureus-necrotizing, community-acquired pneumonia: risk factors and impact on survival date: 2013-08-01 words: 3463 flesch: 36 summary: Death occurred in 75.8% of severe leukopenia cases with median survival time of 4 days, and in 16.3% of cases with leukocyte count >3,000/mL (P<0.001). Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidinsecreting Staphylococcus aureus Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive Staphylococcus aureus: first reported case in the United Kingdom Destructive pulmonary embolism in a patient with community-acquired staphylococcal bacteremia Comparison of community-and health care-associated methicillinresistant Staphylococcus aureus infection Epidemiology and outcomes of community-associated methicillinresistant Staphylococcus aureus infection Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus Severe sepsis and septic shock in the emergency department Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils Diagnosis of a predisposition of retinoblastoma at the DNA level Community-associated methicillinresistant Staphylococcus aureus in outpatients Age-related changes in human hematopoietic stem/progenitor cells HTLV keywords: aureus; cases; count; leukopenia; patients; pneumonia; staphylococcus cache: cord-001050-lq9tp20z.txt plain text: cord-001050-lq9tp20z.txt item: #3 of 79 id: cord-001322-7xmxcm35 author: Walden, Andrew P title: Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort date: 2014-04-01 words: 4294 flesch: 41 summary: In one study, the death rate of ICU patients between 28 days and 6 months was 9% in patients with sepsis, similar to the 8% seen in ICU patients without sepsis [36] and the 10% found in the present study. This compares to an increase in mortality from 18.2% at 30 days to 24.8% at 90 days in the subgroup of ICU patients in the PORT study [24] and an increase from 17.3% to 34.8% at 12 months in the GenIMS cohort of ICU patients [3] . keywords: cap; community; icu; mortality; outcome; patients; pneumonia; severe; study cache: cord-001322-7xmxcm35.txt plain text: cord-001322-7xmxcm35.txt item: #4 of 79 id: cord-002227-x1ddi8wg author: Li, Wanli title: Emergency treatment and nursing of children with severe pneumonia complicated by heart failure and respiratory failure: 10 case reports date: 2016-07-29 words: 4026 flesch: 33 summary: A single-center feasibility study Noninvasive ventilation in children: A review Milrinone combined with dopamine for child pneumonia complicated with heart failure Experimental study of relation of fever to cerebral edema In summary, positive and effective nursing can promote the rehabilitation of children patients, which can be reinforced with adequate communication with the parents and/or caretakers. keywords: blood; children; disease; failure; heart; oxygen; patients; pneumonia; rate; treatment cache: cord-002227-x1ddi8wg.txt plain text: cord-002227-x1ddi8wg.txt item: #5 of 79 id: cord-002757-upwe0cpj author: Sullivan, Kathleen E. title: Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies date: 2017-08-07 words: 24227 flesch: 37 summary: Importantly, after a novel PIDD has been described, subsequent reports often reveal a wider variation in associated infections and cellular findings, often without clear genotype-phenotype correlations [320] [321] Human infection, called Cat Scratch Disease, is assumed to involve inoculation of Bartonella-infected flea feces into the skin during a cat scratch. keywords: associated; azole; bartonella; cases; cause; cell; children; chronic; clinical; cns; countries; days; deficiency; dengue; diagnosis; disease; epidemiology; fever; hiv; human; immune; immunodeficiency; immunoglobulin; individuals; infection; influenza; mandrillaris; patients; pcr; pidd; primary; resistance; review; risk; skin; species; susceptibility; symptoms; syndrome; therapy; tick; transmission; treatment; vaccination; vaccine; virus cache: cord-002757-upwe0cpj.txt plain text: cord-002757-upwe0cpj.txt item: #6 of 79 id: cord-004949-icsey27p author: Fernandez-Botran, Rafael title: Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia date: 2014-02-21 words: 4052 flesch: 39 summary: Compared to non-severe CAP patients, the severe CAP group showed higher plasma levels of pro- and anti-inflammatory cytokines but in contrast, lower sputum concentrations of pro-inflammatory cytokines. However, neutrophils from severe CAP patients showed reduced respiratory burst activity compared to the non-severe group. keywords: cap; cytokines; group; neutrophil; patients; pneumonia; response; samples; sputum; study cache: cord-004949-icsey27p.txt plain text: cord-004949-icsey27p.txt item: #7 of 79 id: cord-005646-xhx9pzhj author: None title: 2nd World Congress on Pediatric Intensive Care 1996 Rotterdam, The Netherlands, 23–26 June 1996 Abstracts of Oral Presentations, Posters and Nursing Programme date: 1996 words: 72090 flesch: 51 summary: Objective: To assess the normal ,gastric intramucosal pH ~Hi) by tonometry in healthy children Patients and methods: Twelve healthy children (6 males and 6 females) with age rmaged from 6 months to 12 years scheduled for minor plastic or urologic surgery. Pain relief was good (VRS less 2) in 53 children -94.6 % of study patients. keywords: acute; administration; admission; age; airway; analysis; ards; arterial; average; babies; blood; brain; cardiac; care; cases; changes; chest; children; complications; conclusion; cpb; criteria; data; days; death; diagnosis; difference; disease; dose; drug; duration; ecmo; effects; failure; flow; gas; group; heart; high; hospital; hours; hypertension; icu; ill; incidence; increase; infants; infusion; initial; injury; intensive; levels; life; lung; management; mean; measurements; mechanical; median; medical; methods; minutes; months; mortality; neonatal; neonates; newborns; nitric; non; nurses; outcome; oxide; oxygenation; parameters; patients; peak; pediatric; period; phi; picu; plasma; post; present; pressure; prism; pulmonary; range; rate; response; results; risk; score; sepsis; severe; severity; study; support; surgery; survivors; syndrome; system; test; therapy; time; total; treatment; unit; use; values; ventilation; volume; weeks; weight; years cache: cord-005646-xhx9pzhj.txt plain text: cord-005646-xhx9pzhj.txt item: #8 of 79 id: cord-006448-elfroq6f author: Hakim, F. A. title: Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature date: 2007-11-21 words: 2167 flesch: 34 summary: Severe adenovirus infections causing significant morbidity and mortality are well described in immunocompromised patients but are extremely rare in healthy immunocompetent adults [1] . However, severe adenovirus infections among immunocompetent adults raised concern when Ryan et al. reported related deaths in two military recruits in 2001 keywords: adenovirus; failure; illness; infection; patients; pneumonia cache: cord-006448-elfroq6f.txt plain text: cord-006448-elfroq6f.txt item: #9 of 79 id: cord-007786-cu831tl7 author: Dondorp, Arjen M. title: Management of Severe Malaria and Severe Dengue in Resource-Limited Settings date: 2019-02-09 words: 4116 flesch: 38 summary: There is insufficient evidence to recommend fluid choice in severe dengue with hypotensive shock, but there is discussion among experts whether there is a role for colloids in severe dengue patients with hypotension, given the prominent role of capillary leak it its pathogenesis. The WHO guidelines for the management of patients with severe dengue distinguish patients with compensated shock from those with decompensated (hypotensive) shock [2, 27] . keywords: children; dengue; fluid; malaria; patients; shock; therapy cache: cord-007786-cu831tl7.txt plain text: cord-007786-cu831tl7.txt item: #10 of 79 id: cord-016057-efc6msf4 author: Blumberg, Lucille title: Severe Malaria: Manifestations, diagnosis, chemotherapy, and management of severe malaria in adults date: 2005 words: 4792 flesch: 42 summary: The prognostic and pathophysiologic role of pro-and anti-inflammatory cytokines in severe malaria The treatment of malaria Blood examination and prognosis in acute falciparum malaria Intraleucocytic malaria pigment and prognosis in severe malaria Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay African malaria vector in European aircraft Quinine loading dose in cerebral malaria Pharmacokinetics of quinine in obesity Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon Pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria Quinine and severe falciparum malaria in late pregnancy The effects of antimalarial drugs on ventricular repolarization Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Vietnam Overview of clinical studies on artemisinin derivatives in Thailand Strategies for the prevention of antimalarial drug resistance: rationale for combination therapy for malaria The disposition of intramuscular artemether in children with cerebral malaria: a preliminary study An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria Case report and review Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: A meta-analysis What is the future of exchange transfusion in severe malaria? Predictors of mortality in severe malaria: A two-year experience in a non-endemic area keywords: africa; blood; cerebral; disease; failure; falciparum; malaria; patients; quinine; treatment cache: cord-016057-efc6msf4.txt plain text: cord-016057-efc6msf4.txt item: #11 of 79 id: cord-017715-99ri6x0y author: Zhou, Bo-Ping title: SARS date: 2015-07-25 words: 8861 flesch: 42 summary: On March 21, 2003 , Hong Kong University fi rstly separated and cultured coronavirus from the nasopharyngeal specimen of SARS patients by Vero cells, and then several laboratories of Canada and America disease center and SARS international coordination group also cultured coronavirus. According to the report of WHO, SARS epidemics was found in total 29 The main source of infection is SARS patients, and other infectious sources such as animals need to be further consolidated. keywords: changes; chest; coronavirus; density; disease; head; lesions; lung; patients; phase; pulmonary; ray; sars; shadows; syndrome cache: cord-017715-99ri6x0y.txt plain text: cord-017715-99ri6x0y.txt item: #12 of 79 id: cord-017758-zfudssm9 author: Fong, I. W. title: Emergence of New Tickborne Infections date: 2017-02-08 words: 8057 flesch: 45 summary: [Bunyaviridae]: a novel species of the genus Phlebovirus and its relationship with other emerging tickborne phleboviruses Fever with thrombocytopenia associated with novel bunyavirus in China Metagenomic analysis of fever, thrombocytopenia and leucopenia syndrome [FTLS] in Hennan Province, China: discovery of a new bunyavirus Evolutionary and molecular analysis of the emergent severe fever with thrombocytopenia syndrome virus Characterization of the Uukuiemi virus group [Phlebovirus: Bunyaviridae]: evidence of seven distinct species Severe fever with thrombocytopenia syndrome, an emerging tickborne zoonosis Bunyavirus-vector interactions Identification of two severe fever with thrombocytopenia syndrome virus strains originating from reassortment Clinical and epidemiological study on severe fever with thrombocytopenia syndrome in Yiyuan County Severe fever with thrombocytopenia syndrome virus Emerging hemorrhagic fever in China caused by a novel bunyavirus SFTSV Characterization of severe fever with thrombocytopenia syndrome in rural regions of Zhejiang A study of seroprevalence and rates of asymptomatic viremia of severe fever with thrombocytopenia syndrome virus among Chinese blood donors Systemic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics Seroprevalence of antibodies against SFTS virus infection in farmers and animals Acute thrombocytopenia, leucopenia, and multiorgan dysfunction: the first case of SFTS Bunyavirus outside of China? Severe fever with thrombocytopenia syndrome, South Korea Severe fever with thrombocytopenia virus The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China SFTS virus in ticks in endemic areas of China Prevalence of severe fever with thrombocytopenia syndrome virus in Haemaphipalis longicornis ticks in South Korea Severe fever with thrombocytopenia syndrome virus in ticks collected from humans, South Korea Preparation and evaluation of recombinant severe fever with thromboctypenia syndrome virus nucleocapsid protein for detection of total antibodies in human and animal sera by double-antigen sandwich enzyme-linked immunosorbent assay A cross-sectional survey of fever with thrombocytopenia syndrome virus infection of domestic animals in Laizhou City Severe fever with thrombocytopenia syndrome virus among domesticated animals Investigation of severe fever with thrombocytopenia syndrome The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathogenic mechanisms of a new hemorrhagic fever Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model SFTS virus infection in nonhuman primates Immunization with recombinant SFTSV/NSs protein does not promote viral clearance in SFTSV-infected C57BL/6J mice Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome keywords: animals; borrelia; cases; china; disease; fever; host; human; infection; patients; sftsv; syndrome; thrombocytopenia; thrombocytopenia syndrome; tickborne; ticks; transmission; virus cache: cord-017758-zfudssm9.txt plain text: cord-017758-zfudssm9.txt item: #13 of 79 id: cord-017870-5fu4uswq author: Feldman, C. title: Falciparum Malaria date: 2010-05-20 words: 7133 flesch: 45 summary: A computed tomography study APACHE II scoring for predicting outcome in cerebral malaria The management of status epilepticus Acute renal failure in patients with severe falciparum malaria Treatment of malarial acute renal failure by hemodialysis Fluid overload in multiple organ dysfunction syndrome: prediction of survival Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective randomized trial Association between mitochondrial dysfunction and severity and outcome of septic shock Editorial response: Exchange blood transfusion in severe falciparum malaria -the debate goes on Severe hypoglycemia and hyperinsulinemia in falciparum malaria Shock complicating severe falciparum malaria in European adults The immunology and pathogenesis of malaria during pregnancy Quinine therapy in severe Plasmodium falciparum malaria during pregnancy in Sudan Pathophysiology of fatal falciparum malaria in African children Indicators of life-threatening malaria in African children The pathogenesis of severe malaria in African children Overlap in the clinical features of pneumonia and malaria in African children Severe malaria in children in Papua New Guinea Neurological sequelae of cerebral malaria in children What's new in malaria control? Current status of malaria control Chemoprophylaxis of malaria The malaria vaccine: anti-parasite or anti-disease? Endotoxin Cerebral malaria: mediators, mechanical obstruction or more? Roles of tumour necrosis factor in the illness and pathology of malaria Proposed link between cytokines, nitric oxide and human cerebral malaria The cytokine theory of human cerebral malaria Cerebral malaria -a neurovascular pathology with many riddles still to be solved Neurological complications of critical medical illnesses and transplantation The laboratory diagnosis of malaria Development of a real-time PCR assay for detection of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale for routine clinical diagnosis Evaluation of the Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers Performance of the Now Malaria rapid diagnostic test with returned travellers: a 2-year retrospective study in a French teaching hospital Fluid management of severe falciparum malaria in African children Pre-transfusion management of children with severe malarial anaemia: a randomized controlled trial of intravascular volume expansion Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: A meta-analysis Diagnosis and treatment of malaria in Britain Current concepts: the treatment of malaria High first dose quinine regimen for treating severe malaria. keywords: blood; cerebral; children; development; disease; falciparum; infection; malaria; parasite; patients; plasmodium; quinine; treatment cache: cord-017870-5fu4uswq.txt plain text: cord-017870-5fu4uswq.txt item: #14 of 79 id: cord-018764-02l423mk author: Clark, Ian A. title: The molecular basis of paediatric malarial disease date: 2007 words: 10015 flesch: 31 summary: Severe falciparum malaria is an acute systemic disease that can affect multiple organs, including those in which few parasites are found. Metabolic acidosis, often associated with hyperlactataemia, has been described in African children with severe falciparum malaria [111, 112] . keywords: acidosis; blood; cell; cerebral; children; cytokines; disease; factor; falciparum; human; infection; lactate; malaria; patients; plasmodium; sepsis; tnf cache: cord-018764-02l423mk.txt plain text: cord-018764-02l423mk.txt item: #15 of 79 id: cord-023169-obupqcua author: Chierakul, Wirongrong title: Leptospirosis date: 2013-10-21 words: 4985 flesch: 39 summary: using a new solid medium, LVW agar Antibiotic prophylaxis for leptospirosis A century of Leptospira strain typing Genome reduction in Leptospira borgpetersenii reflects limited transmission potential Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis Diagnostic accuracy of real-time PCR assays targeting 16S rRNA and lipL32 genes for human leptospirosis in Thailand: a case-control study A waterborne outbreak of leptospirosis An institutional outbreak of leptospirosis in Chennai, South India Human-to-human transmission of Leptospira interrogans by milk The globalization of leptospirosis: worldwide incidence trends Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world Report of the second meeting of the leptospirosis burden epidemiology reference group Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen In vitro evidence for immune evasion activity by human plasmin associated to pathogenic Leptospira interrogans Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism New insights into the pathogenicity of leptospires: evasion of host defences Liver biopsy in human leptospirosis: a light and electron microscopy study Kidney biopsies in human leptospirosis: a biochemical and electron microscopy study Acute kidney injury in human leptospirosis: an immunohistochemical study with pathophysiological correlation Immunohistochemical and in situ hybridization studies of the liver and kidney in human leptospirosis Activation of the coagulation cascade in patients with leptospirosis Lung lesions in human leptospirosis: microscopic, immunohistochemical, and ultrastructural features related to thrombocytopenia Melbourne: MediSci Factors associated with clinical leptospirosis: a populationbased case-control study in the Seychelles (Indian Ocean) Severe leptospirosis is a multi-system disease. keywords: acute; cases; disease; haemorrhage; human; illness; jaundice; leptospira; leptospirosis; pathogenic; patients; serovar cache: cord-023169-obupqcua.txt plain text: cord-023169-obupqcua.txt item: #16 of 79 id: cord-026031-hnf5vayd author: Ford, Richard B. title: Emergency Care date: 2009-05-21 words: 112481 flesch: 42 summary: animal patients. The normal CVP for small animal patients is 0 to 5 cm H 2 O. Values less than zero are associated with absolute or relative hypovolemia. keywords: abnormalities; acute; administer; administration; airway; animal; bandage; blood; blood pressure; body; cardiac; care; cases; catheter; cats; cause; charcoal; control; crystalloid; damage; days; decrease; diagnosis; disease; dogs; dose; drugs; dysrhythmias; edema; effects; effusion; emergency; emesis; examination; exposure; failure; fluid; following; function; gastrointestinal; heart; hemorrhage; hours; infection; ingestion; injury; intravenous; kg iv; kg po; lavage; loss; management; minutes; monitor; needle; normal; obstruction; occurs; oxygen; pain; patient; perform; perfusion; place; plasma; presence; present; pressure; pulmonary; radiographs; rate; renal; result; risk; saline; secondary; seizures; serum; shock; signs; skin; sodium; solution; supplemental; therapy; thoracic; time; tissue; toxicity; trauma; treatment; tube; urine; volume; vomiting; water; wound cache: cord-026031-hnf5vayd.txt plain text: cord-026031-hnf5vayd.txt item: #17 of 79 id: cord-026653-094bk0t0 author: Gülsen, Askin title: Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events* date: 2020-06-24 words: 14021 flesch: 44 summary: ADA were detected in 2-8 % of treated patients, and two subjects developed serum sickness or serum sickness-like reactions. In the last published FDA label, IRs and cytokine release syndrome were reported in 92 % of treated patients, but epinephrine or atropine was administered in 0.6 % of these patients [54] . keywords: anaphylaxis; assessment; cancer; drug; fda; hsrs; hypersensitivity; infusion; irs; isrs; labels; pain; patients; rash; reactions; report; study; symptoms; treatment; urticaria cache: cord-026653-094bk0t0.txt plain text: cord-026653-094bk0t0.txt item: #18 of 79 id: cord-030369-4dn02a35 author: Peng, Liang title: Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure) date: 2019-05-21 words: 35873 flesch: 36 summary: Of the possible complications occurring in liver failure patients, bleeding is the most common and severe. Concomitant infection in liver failure patients has the following characteristics: (1) a high incidence; (2) infection may occur at different sites either simultaneously or sequentially, and abdominal and biliary tract infection is the most common. keywords: aclf; acute; acute hepatitis; alf; bilirubin; blood; cause; changes; chronic; chronic hepatitis; cirrhosis; clinical; diagnosis; encephalopathy; factors; failure patients; gene; hbv; hbv infection; hepatic; hepatitis; hepatitis patients; immune; infection; liver cells; liver cirrhosis; liver damage; liver disease; liver failure; liver function; liver injury; liver transplantation; mutation; necrosis; patients; prognosis; protein; serum; severity; stage; studies; study; therapy; treatment; type; type hepatitis; type patients; virus cache: cord-030369-4dn02a35.txt plain text: cord-030369-4dn02a35.txt item: #19 of 79 id: cord-032181-gmcugd8h author: Song, Jian-Xin title: Main Complications of AECHB and Severe Hepatitis B (Liver Failure) date: 2019-05-21 words: 51195 flesch: 34 summary: If liver disease patients have other lung diseases (such as chronic bronchitis, emphysema and pneumonia, and pleural effusion, etc.), then significant respiratory symptoms may occur. in liver cirrhosis patients with ascites that paracentesis should be performed after admission to determine whether SBP exist. keywords: acid; activity; acute; addition; ammonia; arterial; ascites; bacterial; bleeding; blood; body; brain; cause; cells; chronic; circulation; cirrhosis; coagulation; diagnosis; diseases; dysfunction; encephalopathy; endotoxin; factors; function; hepatic; hepatitis patients; high; hps; hps patients; hrs; hypoxemia; increase; infection; liver; liver cells; liver cirrhosis; liver disease; liver failure; liver function; liver transplantation; lps; manifestations; metabolic; oxygen; patients; plasma; platelet; pressure; protein; pulmonary; rate; receptor; renal; respiratory; role; serum; study; symptoms; syndrome; system; systemic; test; time; tract; treatment; type; vascular cache: cord-032181-gmcugd8h.txt plain text: cord-032181-gmcugd8h.txt item: #20 of 79 id: cord-033833-woref5g8 author: Fragoso-Saavedra, Sergio title: A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol date: 2020-10-16 words: 2761 flesch: 32 summary: In addition to the approved uses of i-ACh-e in human pathology, there is evidence in various murine models of their efficacy in experimental sepsis and severe inflammatory response [12, 19, 21] , suggesting that i-ACh-e drugs have a potential immunomodulatory effect in patients with severe systemic inflammatory response syndrome. key: cord-033833-woref5g8 authors: Fragoso-Saavedra, Sergio; Iruegas-Nunez, David A.; Quintero-Villegas, Alejandro; García-González, H. Benjamín; Nuñez, Isaac; Carbajal-Morelos, Sergio L.; Audelo-Cruz, Belem M.; Arias-Martínez, Sarahi; Caro-Vega, Yanink; Calva, Juan José; Luqueño-Martínez, Verónica; González-Duarte, Alejandra; Crabtree-Ramírez, Brenda; Crispín, José C.; Sierra-Madero, Juan; Belaunzarán-Zamudio, Pablo F.; Valdés-Ferrer, Sergio I. title: A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol date: 2020-10-16 journal: BMC Infect Dis DOI: 10.1186/s12879-020-05485-7 sha: doc_id: 33833 cord_uid: woref5g8 BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). keywords: covid-19; inflammatory; participants; patients; pyridostigmine; study; ventilation cache: cord-033833-woref5g8.txt plain text: cord-033833-woref5g8.txt item: #21 of 79 id: cord-035020-mhs7yext author: Simadibrata, Daniel Martin title: Platelet-to-lymphocyte ratio, a novel biomarker to predict the severity of COVID-19 patients: A systematic review and meta-analysis date: 2020-11-02 words: 3252 flesch: 45 summary: However, with the removal of Yang et al., the pooled analysis still showed a statistically significant higher PLR value on admission in severe COVID-19 in comparison to non-severe COVID-19 patients. The pooled effect size meta-analysis using the fixedeffects model showed a significantly higher PLR value on admission in severe COVID-19 patients than non-severe COVID-19 patients (SMD 0.57; 95%CI 0.41-0.72). keywords: admission; analysis; covid-19; patients; plr; severity; studies cache: cord-035020-mhs7yext.txt plain text: cord-035020-mhs7yext.txt item: #22 of 79 id: cord-253077-61fmul8c author: Vabret, Nicolas title: Immunology of COVID-19: current state of the science date: 2020-05-06 words: 20264 flesch: 30 summary: Tan et al. proposed a prognostic model based on lymphocyte counts at two time points: patients with less than 20% lymphocytes at days 10-12 from the onset of symptoms and less than 5% at days 17-19 had the worst outcomes in this study (Tan et al., 2020a) . Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020; Ju et al., 2020; . keywords: 2020b; antibodies; antibody; blood; cd4; cells; coronavirus; cov-2; covid-19; covid-19 patients; cytokine; disease; et al; hcq; human; ifn; immune; infection; inflammatory; levels; lung; mers; patients; potential; protein; respiratory; responses; sars; sars coronavirus; severity; specific; studies; study; syndrome; t cells; treatment; vaccine cache: cord-253077-61fmul8c.txt plain text: cord-253077-61fmul8c.txt item: #23 of 79 id: cord-253502-v2hh3w3r author: Leung, C.W. title: Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children date: 2004-11-05 words: 8632 flesch: 40 summary: Important questions to ask in the 'peace time' include: (1) history of recent travel to pre-viously SARS-affected areas or areas with an increased likelihood of animal to human transmission of SARS-CoV infection; (2) close contact with a suspected SARS patient; (3) history of recent hospitalisation or contact with a healthcare facility; (4) individuals who are either healthcare workers or laboratory workers with potential exposure to SARS patients or live SARS-CoV; and (5) link to a cluster of cases of unexplained respiratory illness in the community. Sputum specimens appear to have a higher diagnostic yield but productive cough is uncommon in SARS patients in the early phase of illness and sputum is difficult to obtain in children. keywords: acute; adults; children; clinical; coronavirus; cov; diagnosis; disease; illness; infection; patients; pcr; sars; severe; syndrome; treatment cache: cord-253502-v2hh3w3r.txt plain text: cord-253502-v2hh3w3r.txt item: #24 of 79 id: cord-254419-qw83atrx author: Bhattacharyya, Rajat title: The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review date: 2020-08-25 words: 5908 flesch: 29 summary: Statins, another group of drugs that have anti-inflammatory and antithrombotic properties, have also been studied in COVID-19 patients; a retrospective study showed a favorable recovery profile and lower all-cause mortality with the use of statins in 1219 hospitalized patients with COVID-19 A pilot trial of adding tocilizumab therapy in patients with severe COVID-19 disease in combination with standard therapy of lopinavir, methylprednisolone, and oxygen therapy showed remarkable short-term clinical responses in 20 out of 21 patients within 2 weeks of tocilizumab therapy [57] . keywords: acute; anticoagulation; cells; coronavirus; covid-19; disease; failure; infection; inflammatory; patients; pulmonary; study; thrombosis; trials cache: cord-254419-qw83atrx.txt plain text: cord-254419-qw83atrx.txt item: #25 of 79 id: cord-254809-o454k6ae author: He, Bing title: The Metabolic Changes and Immune Profiles in Patients With COVID-19 date: 2020-08-28 words: 4764 flesch: 55 summary: Serum D-dimer and FDP were 9.89 mg/L (IQR, 3.62–22.85) and 32.7 mg/L (IQR, 12.8–81.9), and a large number of RBC (46/μL (IQR, 4–242) was presented in urine, a cue of disseminated intravascular coagulation (DIC) in severe patients. (D) serum IL-6 concentration between mild patients (n = 32) and severe patients (n = 21). keywords: cases; cells; children; covid-19; infection; iqr; monocytes; patients cache: cord-254809-o454k6ae.txt plain text: cord-254809-o454k6ae.txt item: #26 of 79 id: cord-255174-h1izji2g author: Wei, Yuan-Yuan title: Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China date: 2020-04-17 words: 958 flesch: 48 summary: The mean age was 49.03 years in severe patients and 40.83 years in non-severe patients, with a significant difference (p=0.007). The prevalence of shortness of breath was 73.33% in severe patients, which was significantly greater than the 28.47% prevalence in non-severe patients (p<0.001). keywords: covid-19; patients; risk cache: cord-255174-h1izji2g.txt plain text: cord-255174-h1izji2g.txt item: #27 of 79 id: cord-255490-gyq6cpc9 author: Wang, Chang‐Zheng title: Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia date: 2020-05-29 words: 2325 flesch: 48 summary: Severe patients often develop dyspnea and/or hypoxemia one week after onset, and may even rapidly progress to acute respiratory distress syndrome (ARDS), septic shock, hard-to-correct metabolic acidosis, bleeding and coagulation dysfunction, and multiple organ failure 2 . Early identification of patients with possible deterioration of the disease is particularly important for controlling the proportion of severe patients and reduce the mortality. keywords: coronavirus; count; covid-19; disease; patients cache: cord-255490-gyq6cpc9.txt plain text: cord-255490-gyq6cpc9.txt item: #28 of 79 id: cord-257344-d13at1y5 author: Ghasemiyeh, Parisa title: COVID-19 Outbreak: Challenges in Pharmacotherapy Based on Pharmacokinetic and Pharmacodynamic Aspects of Drug Therapy in Patients with Moderate to Severe Infection date: 2020-09-18 words: 5690 flesch: 35 summary: According to recently published researches, the most common clinical presentations in COVID-19 patients were fever in 83% to 98% of patients, dry cough in 76 to 82%, and fatigue or myalgia in 11 to 44% of them. So close patient monitoring is required in COVID-19 patients with pre-existing cardiovascular disease who are planned to treat with lopinavir/ritonavir and sometimes alternative drugs might be considered 52 . keywords: antiviral; chloroquine; coronavirus; covid-19; disease; drug; hydroxychloroquine; lopinavir; patients; potential; ribavirin; ritonavir; treatment cache: cord-257344-d13at1y5.txt plain text: cord-257344-d13at1y5.txt item: #29 of 79 id: cord-258307-nsdhvc8w author: Maki, Dennis G. title: SARS Revisited: The Challenge of Controlling Emerging Infectious Diseases at the Local, Regional, Federal, and Global Levels date: 2011-10-20 words: 5024 flesch: 35 summary: [20] [21] [22] Because SARS is such a unique human viral infection and induces such an unusually severe systemic inflammatory response, 18, 19 it will be important to closely follow survivors of severe SARS for considerably longer to be certain that latently expressed progressive pulmonary fibrosis does not occur. Whereas uncontrolled studies of treated cohorts in Asia have suggested that using moderate doses of corticosteroids, 1 to 2 mg/kg of a prednisone-equivalent daily, at the first evidence of severe SARS, specifically hypoxemia, may improve survival, 59,61,62 corticosteroid therapy for SARS has had serious adverse effects, 63 and a single randomized trial of preemptive pulse corticosteroid therapy did not show benefit. keywords: avian; control; cov; health; human; influenza; outbreak; patients; sars; spread; syndrome; virus cache: cord-258307-nsdhvc8w.txt plain text: cord-258307-nsdhvc8w.txt item: #30 of 79 id: cord-260238-2p209g2p author: Peiris, J S M title: Severe acute respiratory syndrome date: 2004-11-30 words: 6299 flesch: 30 summary: In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells HIV protease inhibitor nelfinavir inhibits replication of SARSassociated coronavirus Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs Interferon-β 1a and SARS coronavirus replication Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α The antiviral effect of interferon-β against SARS coronavirus is not mediated by MxA protein Old drugs as lead compounds for a new disease? HLA-B*4601 has been associated with severe SARS disease in Taiwan 94 but not Hong Kong 95 . keywords: associated; cells; coronavirus; cov; disease; health; human; individuals; infection; outbreak; protein; sars; spike; syndrome; transmission cache: cord-260238-2p209g2p.txt plain text: cord-260238-2p209g2p.txt item: #31 of 79 id: cord-261633-r4qlbnc5 author: Xie, Guo-Hao title: Defensins and Sepsis date: 2014-08-19 words: 2928 flesch: 35 summary: Sepsis, severe sepsis, and septic shock represent a continuum of clinical syndromes which are common complications observed in patients with infection, trauma, and major surgeries [1] [2] [3] . Epidemiology studies demonstrated that severe sepsis has a population prevalence of 300/100 000 in the United States and counts for 10-30% of the intensive care unit (ICU) patients [4] [5] [6] . keywords: defensins; expression; gene; human; lung; number; patients; sepsis; studies cache: cord-261633-r4qlbnc5.txt plain text: cord-261633-r4qlbnc5.txt item: #32 of 79 id: cord-263031-cco2vh0f author: Vultaggio, Alessandra title: Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement date: 2020-06-05 words: 2875 flesch: 31 summary: It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. 36 Benralizumab and omalizumab showed an increase in AEs with low to moderate certainty in severe allergic asthma. keywords: asthma; biologicals; copyright; disease; patients; sars; treatment; type cache: cord-263031-cco2vh0f.txt plain text: cord-263031-cco2vh0f.txt item: #33 of 79 id: cord-270533-s2d3q4ob author: Lau, Yu-Lung title: SARS: future research and vaccine date: 2004-11-05 words: 3001 flesch: 40 summary: Further understanding of the ecology of SARS CoV in human and animals will help prevent future cross species transmission. Further understanding of the ecology of SARS CoV in human and animals will help prevent future cross species transmission. keywords: coronavirus; cov; disease; research; response; sars; syndrome cache: cord-270533-s2d3q4ob.txt plain text: cord-270533-s2d3q4ob.txt item: #34 of 79 id: cord-274802-7ioiwsd8 author: Varghese, Praveen Mathews title: Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies date: 2020-08-19 words: 19710 flesch: 31 summary: Unlike SARS, COVID-19 patients had the highest viral load near presentation, which could account for the fast-spreading nature of this epidemic. In a study involving COVID-19 patients in Hong Kong recorded high viral load on presentation with the onset of symptoms and also when the symptoms are mild (83) . keywords: activation; acute; antibodies; case; cells; china; complement; coronavirus; cov-2; covid-19; covid-19 patients; disease; dose; drug; high; human; infection; inflammation; injury; levels; novel; pathogenesis; patients; plasma; pneumonia; protein; response; sars; spike; studies; study; syndrome; system; transmission; treatment; trial; vaccine cache: cord-274802-7ioiwsd8.txt plain text: cord-274802-7ioiwsd8.txt item: #35 of 79 id: cord-275154-vwnpred5 author: Bermejo-Martin, Jesus F title: Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza date: 2009-12-11 words: 4654 flesch: 41 summary: Increase of IL-17 and TNF-α in hospitalized patients over control indicated that they also parallel severe disease, but the significantly higher levels of IL-17 and TNF-α in severe non critical patients compared to mild (difference not found for critical ones), could reflect a beneficial role of these cytokines in this particular subset of patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). keywords: cytokines; disease; hospitalized; infection; influenza; levels; mediators; nvh1n1; patients; responses; serum; virus cache: cord-275154-vwnpred5.txt plain text: cord-275154-vwnpred5.txt item: #36 of 79 id: cord-275506-3t5gf66c author: Agbuduwe, Charles title: Hematolological Manifestations of COVID‐19: From Cytopenia to Coagulopathy date: 2020-07-14 words: 4288 flesch: 27 summary: [17] In addition to a significant reduction in both CD4+ and CD8+ T lymphocyte subsets in COVID-19 patients, severe cases had much lower CD8+ lymphocytes and a subsequent increase positively correlated with improved clinical outcomes. [14] Similar findings were reported in a French cohort study with mild thrombocytopenia identified in about a quarter of COVID-19 patients on admission to hospital and this was independently predictive of the risk of admission to ICU, mechanical ventilation or death. keywords: article; blood; cases; cov-2; covid-19; disease; patients; sars; study cache: cord-275506-3t5gf66c.txt plain text: cord-275506-3t5gf66c.txt item: #37 of 79 id: cord-277217-jh4qmoso author: Ortiz, Justin R. title: Clinical care for severe influenza and other severe illness in resource‐limited settings: the need for evidence and guidelines date: 2013-08-27 words: 3671 flesch: 31 summary: Euro surveillance: bulletin europeen sur les maladies transmissibles Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study Research during public health crises: a systematic review of severe pandemic influenza management Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) 2009 infection in Canada Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1) Extracorporeal membrane oxygenation for severe influenza A (H1N1) acute respiratory distress syndrome: a prospective observational comparative study Epidemiology and etiology of childhood pneumonia Viral etiology of severe pneumonia among Kenyan infants and children Influenza is a major contributor to childhood pneumonia in a tropical developing country Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis Mortality associated with influenza and respiratory syncytial virus in the United States Elevated influenza-related excess mortality in South African elderly individuals Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of america Incidence and outcomes of acute lung injury The epidemiology of sepsis in the United States from 1979 through 2000 Treatment of sepsis Critical care and the global burden of critical illness in adults The Acute Respiratory Distress Syndrome Network. Despite the absence of sophisticated equipment and abundant resources, including ICUs, it is likely that many lives in resource-limited settings can be saved by promoting the basic tenets of severe illness management. keywords: care; h1n1; illness; influenza; management; pandemic; resource; settings cache: cord-277217-jh4qmoso.txt plain text: cord-277217-jh4qmoso.txt item: #38 of 79 id: cord-277347-5innqoip author: Huang, Y. title: A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19 date: 2020-04-24 words: 2950 flesch: 53 summary: Of the risk factors evaluated, we found the levels of D-dimer, CRP, LDH, and PCT are significantly higher in severe patients than in non-severe patients (Figure3) . Moreover, we tracked dynamic changes during the process of COVID-19, and found CRP, D-dimer, LDH, PCT kept in high levels in severe patient. keywords: clinical; covid-19; dimer; factors; patients; study cache: cord-277347-5innqoip.txt plain text: cord-277347-5innqoip.txt item: #39 of 79 id: cord-278013-0d6o5w8z author: Omori, Ryosuke title: Ascertainment rate of novel coronavirus disease (COVID-19) in Japan date: 2020-03-10 words: 1312 flesch: 56 summary: The ascertainment rate of non-severe cases was estimated at 0.44 (95% confidence interval: 0.37, 0.50), indicating that unbiased number of non-cases would be more than twice the reported count. The present study aims to estimate the ascertainment rate 10 of non-severe cases, employing a statistical model. keywords: cases; non; preprint cache: cord-278013-0d6o5w8z.txt plain text: cord-278013-0d6o5w8z.txt item: #40 of 79 id: cord-278477-9a7gmzz3 author: Huh, Kyungmin title: Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: a matter of sexual dimorphism? date: 2020-10-21 words: 3235 flesch: 44 summary: Propensity scores (PS) of severe COVID-19 risk were calculated using logistic regression with the following covariates: age, sex, coverage for low income, and CCI. This retrospective study compared BP, and metabolic and kidney function parameters between COVID-19 patients with severe disease (including fatalities) and those with mild-tomoderate disease. keywords: covid-19; disease; health; levels; patients; risk; sex; study cache: cord-278477-9a7gmzz3.txt plain text: cord-278477-9a7gmzz3.txt item: #41 of 79 id: cord-285557-my16g91c author: Berger, A. title: Severe acute respiratory syndrome (SARS)—paradigm of an emerging viral infection date: 2004-01-31 words: 6386 flesch: 40 summary: Koch's postulates fulfilled for SARS virus Critically ill patients with severe acute respiratory syndrome SARS genome patent: symptom or disease? Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China Severe acute respiratory syndrome (SARS): breath-taking progress Electron microscopy for rapid diagnosis of infectious agents in emergent situations SARS coronavirus: a new challenge for prevention and therapy Clinical presentations and outcome of severe acute respiratory syndrome in children Hong Kong Department of Health. Hong Kong researchers reported at the WHO Global Conference on SARS in Kuala Lumpur in June 2003 that SARS patients treated with Kaletra (lopinavir with low-dose ritonavir) plus ribavirin experienced a 50% reduction in death rate. keywords: cases; coronavirus; cov; et al; health; human; organization; patients; sars; syndrome; transmission; world cache: cord-285557-my16g91c.txt plain text: cord-285557-my16g91c.txt item: #42 of 79 id: cord-286683-mettlmhz author: Ortiz-Prado, Esteban title: Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review date: 2020-05-30 words: 13331 flesch: 37 summary: medRxiv Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Temporal dynamics in viral shedding and transmissibility of COVID-19 Presumed asymptomatic carrier transmission of COVID-19 Potential presymptomatic transmission of SARS-CoV-2 Interferon-stimulated genes and their antiviral effector functions RIG-I in RNA virus recognition RNA recognition and signal transduction by RIG-I-like receptors Recognition of viral single-stranded RNA by Toll-like receptors Mechanisms of innate immune evasion in re-emerging RNA viruses Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections Immunopathogenesis of coronavirus infections: implications for SARS Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Middle East respiratory syndrome Interaction of SARS and MERS coronaviruses with the antiviral interferon response SARS and MERS: recent insights into emerging coronaviruses Dysregulation of immune response in patients with COVID-19 in Wuhan Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) Effects of chloroquine on viral infections: an old drug against today's diseases Chloroquine is a potent inhibitor of SARS coronavirus infection and spread In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease COVID-19: consider cytokine storm syndromes and immunosuppression. Three recent examples of these viral jumps include SARS CoV, MERS-CoV and SARS CoV-2 virus. keywords: acute; cases; cells; china; clinical; coronavirus; cov-2; covid-19; disease; health; human; infection; influenza; mers; ncov; novel; novel coronavirus; patients; pneumonia; protein; r n; responses; sars; study; syndrome; treatment; use; vaccine; wuhan cache: cord-286683-mettlmhz.txt plain text: cord-286683-mettlmhz.txt item: #43 of 79 id: cord-286799-q9p5kg65 author: Huang, Huang title: Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis date: 2020-10-05 words: 3605 flesch: 36 summary: Interestingly, the levels of glutamate aminotransferase (ALT) and aspartate aminotransferase (AST) significantly increased for severe patients (P < 0.05). Can some routine clinical characteristics or/and laboratory measurements (or their combination) predict the occurrence of severe cases? keywords: cases; covid-19; factors; patients; pneumonia; rate cache: cord-286799-q9p5kg65.txt plain text: cord-286799-q9p5kg65.txt item: #44 of 79 id: cord-286843-8qh1pblc author: Quah, Jessica title: Impact of microbial Aetiology on mortality in severe community-acquired pneumonia date: 2018-09-04 words: 4065 flesch: 34 summary: The immunology of influenza virusassociated bacterial pneumonia Integrated clinical, pathologic, Virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque Kinetics of coinfection with influenza a virus and Streptococcus pneumoniae Etiology of severe communityacquired pneumonia during the 2013 hajj-part of the MERS-CoV surveillance program Clinical and molecular characterization of rhinoviruses a, B, and C in adult patients with pneumonia Human rhinoviruses and severe respiratory infections: is it possible to identify at-risk patients early? viral pneumonia and acute respiratory distress syndrome Burden of acute respiratory disease of epidemic and pandemic potential in the WHO eastern Mediterranean region: a literature review Global threat of animal influenza viruses of zoonotic concern: then and now Surviving Sepsis campaign: international guidelines for Management of Severe Sepsis and Septic Shock Global and local epidemiology of communityacquired pneumonia: the experience of the CAPNETZ network Global changes in the epidemiology of community-acquired pneumonia Community-acquired pneumonia requiring hospitalization among U.S Adults Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24h of ICU admission Viral infection in patients with severe pneumonia requiring intensive care unit admission Etiology of severe pneumonia in the very elderly Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation The authors would like to thank the following: Ms. Carmen Kam, the resident biostatistician for verification of the study statistical analysis; nurses Ms. Wang Xi Qin, Ms. Goh Yuan Xuan, Ms. Lim Qian Ru for assistance in data collection; senior medical technologist Ms. Heng Ying Xuan, Ms. Lee Hui Zi for assistance in performance of PCR tests; Dr. Tay Tunn Ren for her tutelage in manuscript writing. Polymerase chain reaction Etiology and outcome of severe community acquired pneumonia in immunocompetent adults Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway Epidemiology of community-acquired respiratory tract infections in adults The intensive care global study on severe acute respiratory infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia Molecular diagnosis of respiratory viruses The FilmArray® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens Rapid viral diagnosis for acute febrile respiratory illness in children in the emergency department Clinical utility of on-demand multiplex respiratory pathogen testing among adult outpatients Burden of respiratory viruses in patients with acute respiratory failure Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic Management of severe communityacquired pneumonia: a survey on the attitudes of 468 physicians in Iberia and South America Clinical practice of respiratory virus diagnostics in critically ill patients with a suspected pneumonia: a prospective observational study Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the Management of Community-Acquired Pneumonia in adults Acute management and long-term survival among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome Influenza a (H1N1) vs non-H1N1 ARDS: analysis of clinical course A prospective one-year microbiologic survey of combined pneumonia and respiratory failure The use of polymerase chain reaction amplification for the detection of viruses and Bacteria in severe communityacquired pneumonia keywords: cap; hospital; infections; mortality; pathogens; patients; pneumonia; study; viruses cache: cord-286843-8qh1pblc.txt plain text: cord-286843-8qh1pblc.txt item: #45 of 79 id: cord-287872-i6cahnxd author: Wendt, F. R. title: Host genetic liability for severe COVID-19 overlaps with alcohol drinking behavior and diabetic outcomes and in over 1 million participants date: 2020-11-12 words: 1605 flesch: 34 summary: Five phenotypes were significantly genetically correlated with severe respiratory COVID-19 after multiple testing correction and not correlated (unadjusted p-value >0.05) with hospitalized COVID-19 (Table S3 ) For two COVID-19 phenotypes with h 2 z-scores > 4, severe respiratory COVID-19 and hospitalized COVID-19, we then estimated their genetic correlation (rg) with 4,083 phenotypes from the UK Biobank (UKB, see http://www.nealelab.is/uk-biobank). keywords: causal; covid-19; diabetes; outcomes; phenotypes; preprint cache: cord-287872-i6cahnxd.txt plain text: cord-287872-i6cahnxd.txt item: #46 of 79 id: cord-294700-pb5k21da author: Dulek, Daniel E title: Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute COVID-19 in Pediatric Patients date: 2020-08-18 words: 14549 flesch: 30 summary: A single center experience Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2 COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with COVID-19 in New York City Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis COVID-19 and its implications for thrombosis and anticoagulation Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Type I IFN immunoprofiling in COVID-19 patients Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis Tocilizumab for the treatment of severe coronavirus disease 2019 Interleukin-6: A Masterplayer in the Cytokine Network Impaired immune and acute-phase responses in interleukin-6-deficient mice Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection HBV replication is significantly reduced by IL-6 Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Tocilizumab for treatment of mechanically ventilated patients with COVID-19 Tocilizumab in patients with severe COVID-19: a retrospective cohort study Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes Pilot prospective open, single-arm multicentre study on offlabel use of tocilizumab in patients with severe COVID-19 Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Pneumatosis Intestinalis and Intestinal Perforation in a Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab Anakinra for severe forms of COVID-19: a cohort study Canakinumab in a subgroup of patients with COVID-19 Critical regulation of early Th17 cell differentiation by interleukin-1 signaling Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1 Anakinra Therapy for Non-cancer Inflammatory Diseases Rilonacept and canakinumab European Group Of Clinical I. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis Efficacy and safety of rilonacept Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes Highlights of Prescribing Information Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment The convalescent sera option for containing COVID-19 Use of convalescent plasma therapy in SARS patients in Hong Kong Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection Effectiveness of convalescent plasma therapy in severe COVID-19 patients Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea Treatment with convalescent plasma for COVID-19 patients in Wuhan Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antibody responses to SARS-CoV-2 in patients with COVID-19 Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry Administration FaD Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection Deployment of convalescent plasma for the prevention and treatment of COVID-19 Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis Update on the use of immunoglobulin in human disease: A review of evidence Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis Thrombocytopenia in patients with severe acute respiratory syndrome (review) Incidence and Outcome of Severe and Nonsevere Thrombocytopenia Associated With Zika Virus Infection-Puerto Rico Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis Macrophage Activation Syndrome High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease Type I interferons in infectious disease Interferon-lambda orchestrates innate and adaptive mucosal immune responses COVID-19 and emerging viral infections: The case for interferon lambda A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B keywords: acute; anakinra; children; clinical; coronavirus; cov-2; covid-19; covid-19 patients; cytokine; data; disease; evidence; infection; inflammatory; p t; patients; pediatric; sars; studies; syndrome; therapy; tocilizumab; treatment; use cache: cord-294700-pb5k21da.txt plain text: cord-294700-pb5k21da.txt item: #47 of 79 id: cord-296605-p67twx7a author: LAU, Arthur Chun-Wing title: Management of Critically Ill Patients with Severe Acute Respiratory Syndrome (SARS) date: 2004-03-10 words: 4848 flesch: 34 summary: In this article, we aim to focus on the management of the subgroup of SARS patients who are critically ill. In one-third to half of SARS patients, fever may recur while on immunomodulatory treatment due to superimposed infections, too rapid tailing of corticosteroids or persistently severe and uninhibited cytokine storm. keywords: acute; clinical; corticosteroids; failure; icu; infection; patients; pressure; sars; syndrome; treatment; ventilation cache: cord-296605-p67twx7a.txt plain text: cord-296605-p67twx7a.txt item: #48 of 79 id: cord-297323-l3f12hg4 author: Amor, Sandra title: Innate immunity during SARS‐CoV‐2: evasion strategies and activation trigger hypoxia and vascular damage date: 2020-09-26 words: 4990 flesch: 26 summary: All rights reserved the Acute COVID-19 Cardiovascular Syndrome Neurological associations of COVID-19 The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19 Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding 3D Models of glycosylated SARS-CoV-2 spike protein suggest challenges and opportunities for vaccine development Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy Neuropilin-1 is a host factor for SARS-CoV-2 infection Accessory proteins of SARS-CoV and other coronaviruses Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense Identification of Residues of SARS-CoV nsp1 That Differentially Affect Inhibition of Gene Expression and Antiviral Signaling Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation Like many viruses, SARS‐CoV‐2 has evolved strategies to circumvent innate immune detection including low CpG levels in the genome, glycosylation to shield essential elements including the receptor binding domain, RNA shielding and generation of viral proteins that actively impede anti‐viral interferon responses. keywords: article; cell; copyright; coronavirus; cov-2; covid-19; host; infection; protein; response; rights; rna; sars; syndrome cache: cord-297323-l3f12hg4.txt plain text: cord-297323-l3f12hg4.txt item: #49 of 79 id: cord-299093-zp07aqpm author: Harrison, Andrew G. title: Mechanisms of SARS-CoV-2 transmission and pathogenesis date: 2020-10-14 words: 6401 flesch: 34 summary: A first step in understanding SARS pathogenesis A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Atlas of ACE2 gene expression in mammals reveals novel insights in transmission of SARS-CoV-2 A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2 Angiotensin-converting enzyme 2 protects from severe acute lung failure Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2 Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Virological assessment of hospitalized patients with COVID-2019 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California Evidence for Gastrointestinal Infection of SARS-CoV-2 Enteric involvement of severe acute respiratory syndromeassociated coronavirus infection Evidence of Airborne Transmission of the Severe Acute Respiratory Syndrome Virus Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination Role of air distribution in SARS transmission during the largest nosocomial outbreak in Hong Kong Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Viral load of SARS-CoV-2 in clinical samples Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou Possible modes of transmission of Novel coronavirus SARS-CoV-2: a review SARS: experience at Prince of Wales Hospital, Hong Kong Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center The Twilight of Immunity: Emerging Concepts in Aging of the Immune System Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis Clinical characteristics of 82 cases of death from COVID-19 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Dysregulation of immune response in patients with COVID-19 in Wuhan, China Imbalanced host response to SARS-CoV-2 drives development of COVID-19 SARS-CoV-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients by single-cell sequencing The clinical pathology of severe acute respiratory syndrome (SARS): a report from China Lung pathology of fatal severe acute respiratory syndrome Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Cytokine release syndrome in severe COVID-19 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology C-reactive protein: Ligands, receptors and role in inflammation Neutrophil extracellular traps in COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Regulation of IRF-3 dependent innate immunity by the Papainlike protease domain of the SARS coronavirus Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling Crystal Structure of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Papain-like Protease Bound to Ubiquitin Facilitates Targeted Disruption of Deubiquitinating Activity to Demonstrate Its Role in Innate Immune Suppression Interleukin-1β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING Coronavirus Papain-like Proteases Negatively Regulate Antiviral Innate Immune Response through Disruption of STING-Mediated Signaling Activation and evasion of type I interferon responses by SARS-CoV-2 Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 Evasion of type- Indeed, similar inflammatory milieux have been associated with severe lung pathology in SARS patients, along with the notable 'cytokine storm' that can present in critically ill COVID-19 patients [83, 84] keywords: ace2; cell; coronavirus; cov-2; covid-19; disease; human; infection; lung; patients; respiratory; sars; syndrome; transmission cache: cord-299093-zp07aqpm.txt plain text: cord-299093-zp07aqpm.txt item: #50 of 79 id: cord-299150-1noy0z88 author: Desai, Aakash title: Clinical Trial Endpoints in Severe COVID-19 date: 2020-06-06 words: 686 flesch: 47 summary: However, clinical trials of agents tested for severe COVID19 may not necessarily test for mortality outcomes as the primary endpoint, as was highlighted in the press release of the recent remdesivir trial. Since drugs improving mortality in severe COVID-19 is the most important endpoint to achieve both from clinical and public policy standpoint, we evaluated the type of primary endpoints currently being assessed in randomized controlled trials (RCTs) in severe COVID19. keywords: mortality; trials cache: cord-299150-1noy0z88.txt plain text: cord-299150-1noy0z88.txt item: #51 of 79 id: cord-300559-vuuxthx2 author: Deng, Ming title: Obesity as a Potential Predictor of Disease Severity in Young COVID‐19 Patients: A Retrospective Study date: 2020-06-29 words: 4170 flesch: 49 summary: [34, 35] , and the risk of thrombosis is high for severe COVID-19 patients Logistic regression analysis showed that male, high body mass index (especially obesity), elevated fasting blood glucose and urinary protein positive are all risk factors for severe young COVID‐19 patients. keywords: albumin; article; cases; copyright; covid-19; liver; obesity; patients; study cache: cord-300559-vuuxthx2.txt plain text: cord-300559-vuuxthx2.txt item: #52 of 79 id: cord-302115-r39ser2c author: Matricardi, Paolo Maria title: The first, holistic immunological model of COVID‐19: implications for prevention, diagnosis, and public health measures date: 2020-05-02 words: 3743 flesch: 37 summary: medRxiv preprint 2020 Minimum infective dose of the major human respiratory and enteric viruses transmitted through food and the environment SARS-CoV-2 viral load and the severity of COVID-19 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data SARS-CoV-2 viral load in upper respiratory specimens of infected patients Chest CT Findings in Cases from the Cruise Ship Diamond Princess Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for Accepted Article Among them, hospital doctors frequently exposed to COVID-19 patients are, unfortunately, highly represented. keywords: article; copyright; coronavirus; cov-2; covid-19; patients; pneumonia; respiratory; rights; sars cache: cord-302115-r39ser2c.txt plain text: cord-302115-r39ser2c.txt item: #53 of 79 id: cord-302166-tah3jdw0 author: Zhang, Shen-Ying title: Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? date: 2020-06-18 words: 1602 flesch: 33 summary: The dis coveries of these IEIs demonstrated that severe disease due to primary infection with a common virus that is benign in the general population can result from a monogenic 'hole' in human immunity. Other IEIs underlying severe viral diseases, with incomplete or unknown penet rance, have since been reported 1, 7, 8 . keywords: covid-19; immunity; monogenic; patients cache: cord-302166-tah3jdw0.txt plain text: cord-302166-tah3jdw0.txt item: #54 of 79 id: cord-303196-ltmu3ncu author: Pfitscher, L. C. title: Severe maternal morbidity due to respiratory disease and impact of 2009 H1N1 influenza A pandemic in Brazil: results from a national multicenter cross-sectional study date: 2016-05-21 words: 4528 flesch: 37 summary: The study evaluated severe maternal morbidity cases, from a prospective surveillance, according to the 2009 WHO newly publicized criteria for these conditions [6] . We only have data on severe maternal morbidity cases, comparing less severe (PLTC) to more severe cases (SMO). keywords: cases; disease; h1n1; influenza; maternal; morbidity; mortality; pregnancy; study cache: cord-303196-ltmu3ncu.txt plain text: cord-303196-ltmu3ncu.txt item: #55 of 79 id: cord-305223-go75cs6r author: Wang, Yafei title: Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China date: 2020-08-25 words: 3225 flesch: 48 summary: Patients > 60 years of age and those in the age group 40-60 years had a significantly higher risk of developing severe pneumonia than those < 40 years of age. Respiration Diagnostic value of Ddimer in pulmonary embolism and pneumonia Clinical features of patients infected with 2019 novel coronavirus in Wuhan Change of T lymphocyte and its activated subsets in SARS patients. keywords: cov-2; covid-19; day; dimer; patients; pneumonia; sars; serum cache: cord-305223-go75cs6r.txt plain text: cord-305223-go75cs6r.txt item: #56 of 79 id: cord-305583-p2jp5fiq author: Lalloo, David G. title: UK malaria treatment guidelines 2016 date: 2016-02-12 words: 9463 flesch: 45 summary: Severe falciparum malaria Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria Intraleucocytic malaria pigment and prognosis in severe malaria Pathophysiological and prognostic significance of cerebrospinal-fluid lactate in cerebral malaria The pathophysiologic and prognostic significance of acidosis in severe adult malaria The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults The relationship between age and the manifestations of and mortality associated with severe malaria Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand Treatment of imported malaria in adults: a multicentre study in France Artemisininbased combination therapy for treating uncomplicated malaria Effectiveness of quinine versus artemetherelumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial Therapy of uncomplicated falciparum malaria in Europe: MALT Treatment of acute uncomplicated falciparum malaria with artemetherelumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study Atovaquoneeproguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases Azithromycin for treating uncomplicated malaria Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUA-MAT): an open-label, randomised trial Artesunate versus quinine for treating severe malaria A comparison of artesunate alone with combined artesunate and quinine in the parenteral treatment of acute falciparum malaria Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis Intravenous artesunate for severe malaria in travelers Delayed hemolysis after treatment with parenteral artesunate in African children with severe malariaea double-center prospective study Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence Artemisinin resistance in Plasmodium falciparum malaria A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria A trial of artemether or quinine in children with cerebral malaria The Artemether-Quinine Meta-analysis Study Group. A metaanalysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria Quinine loading dose in cerebral malaria Plasma quinine concentrations in falciparum malaria with acute renal failure Management of severe malaria: interventions and controversies Fluid resuscitation of adults with severe falciparum malaria: effects on acid-base status, renal function, and extravascular lung water Hypoglycemia in African children with severe malaria Severe hypoglycemia and hyperinsulinemia in falciparum malaria Hemofiltration and peritoneal dialysis in infectionassociated acute renal failure in Vietnam Dexamethasone proves deleterious in cerebral malaria N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial High-dose dexamethasone in quininetreated patients with cerebral malaria: a double-blind, placebo-controlled trial Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis Severe falciparum malaria: predicting the effect of exchange transfusion Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria The diagnosis and treatment of malaria in pregnancy A systematic review of the safety and efficacy of artemetherelumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy Management of severe malaria in children: proposed guidelines for the United Kingdom Childhood malaria in East London Mortality after fluid bolus in African children with severe infection Proposed guidelines for severe imported malaria in children need more evidence Advanced paediatric life support: the practical approach Blood transfusion for treating malarial anaemia (Cochrane review) Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Plasmodium vivax resistance to chloroquine? Chloroquine resistance in Plasmodium vivax. keywords: artesunate; blood; children; falciparum; falciparum malaria; grade; malaria; patients; plasmodium; primaquine; quinine; therapy; treatment; vivax cache: cord-305583-p2jp5fiq.txt plain text: cord-305583-p2jp5fiq.txt item: #57 of 79 id: cord-308169-a0ft6wdy author: Custovic, A. title: EAACI position statement on asthma exacerbations and severe asthma date: 2013-11-06 words: 7718 flesch: 30 summary: Recent joint modelling of longitudinal observations on wheezing from parental reports and medical records identified a novel phenotype of persistent troublesome wheeze with high rates of severe asthma exacerbations and healthcare utilization (24) . A decline in lung function has also been associated with severe asthma exacerbations in adult asthma (4) . keywords: airway; asthma; care; childhood; children; clinical; control; disease; exacerbations; lung; need; patients; risk; studies; study; treatment cache: cord-308169-a0ft6wdy.txt plain text: cord-308169-a0ft6wdy.txt item: #58 of 79 id: cord-312486-rumqopg0 author: Jacob, Chaim Oscar title: On the genetics and immunopathogenesis of COVID-19 date: 2020-09-10 words: 11535 flesch: 38 summary: -1 beta in macrophages Influence of glutamine on cytokine production by human gut in vitro Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts A whole-genome association study of major determinants for host control of HIV-1 IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes LY6E impairs coronavirus fusion and confers immune control of viral disease Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome Virus-host interactome and proteomic survey of PBMCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis Immunology of COVID-19: current state of the science Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Host and environmental factors influencing individual human cytokine responses COVID-19: consider cytokine storm syndromes and immunosuppression A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage Dysregulation of immune response in patients with COVID-19 in Wuhan, China Heightened innate immune responses in the respiratory tract of COVID-19 patients Clinical features of patients infected with 2019 novel coronavirus in Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Complement evasion strategies of viruses: an overview The Complement System in COVID-19: Friend and Foe? Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Functional exhaustion of antiviral lymphocytes in COVID-19 patients Clinical and immunological features of severe and moderate coronavirus disease 2019 Complex immune dysregulation in COVID-19 patients with severe respiratory failure Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent Coronaviruses and immunosuppressed patients: the facts during the third epidemic Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 Outbreak in Northern Italy Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implication Longitudinal analyses reveal immunological misfiring in severe COVID-19 Mouse model of SARS-CoV-2 reveals inflammatory role of type I Interferon signaling Persistence of memory in times of COVID-19 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls No one is naïve: the significance of heterologous T-cell immunity Heterologous immunity between viruses Heterologous T cell immunity in severe hepatitis C virus infection Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Convergent antibody responses to SARS-CoV-2 in convalescent individuals Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses Viral kinetics and antibody responses in patients with COVID-19. keywords: ace2; activation; cells; children; complement; coronavirus; cov-2; covid-19; cytokine; disease; expression; host; human; infection; patients; response; risk; sars; syndrome; system; virus cache: cord-312486-rumqopg0.txt plain text: cord-312486-rumqopg0.txt item: #59 of 79 id: cord-316928-ivwz7jxi author: Anzola, Gian Paolo title: Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort date: 2020-09-23 words: 3464 flesch: 44 summary: O2%, lymphocyte count, creatinine, proportion of AST ≥ 32, of creatinine ≥ 1.00 (lab cutoff) and CRP were statistically different both in MILD and in SEVERE RD patients (Tables 1, 2 ). For AST and chronic renal failure, the difference from NO RD was significant only in SEVERE RD patients ( Table 1 ). keywords: arbs; covid-19; disease; mild; patients; severe cache: cord-316928-ivwz7jxi.txt plain text: cord-316928-ivwz7jxi.txt item: #60 of 79 id: cord-317058-anvmj4li author: Liu, Xinkui title: Analysis of clinical features and early warning signs in patients with severe COVID-19: A retrospective cohort study date: 2020-06-26 words: 3366 flesch: 48 summary: A higher number of patients showed signs of dyspnea in the severe group than in the non-severe group in our study, indicating that dyspnea was one of the main symptoms among patients with severe COVID-19; thus, a daily evaluation for dyspnea should be conducted among COVID-19 patients. In this study, we summarized the clinical features of COVID-19 patients and identified the early warning signs of severe COVID-19, which will help physicians determine which patients require further observation. keywords: covid-19; group; lymphocyte; patients; risk; study cache: cord-317058-anvmj4li.txt plain text: cord-317058-anvmj4li.txt item: #61 of 79 id: cord-318319-efqf5e1i author: Yamasaki, Yukitaka title: The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide date: 2020-07-03 words: 2137 flesch: 54 summary: Of the 30 included patients, 12, 14, and 4 were allocated to severe pneumonia, non-severe pneumonia, and non-pneumonia groups, respectively. Patients were divided into three groups: severe pneumonia, non-severe pneumonia, and non-pneumonia. keywords: covid-19; group; non; patients; pneumonia cache: cord-318319-efqf5e1i.txt plain text: cord-318319-efqf5e1i.txt item: #62 of 79 id: cord-322229-a7sz6e3c author: Suryadevara, V. title: Mental Health Status among the South Indian Pharmacy Students during Covid-19 Pandemic Quarantine Period: A Cross-Sectional Study date: 2020-05-12 words: 2264 flesch: 49 summary: The study findings shows the need of conducting more such studies and can be used to prepare appropriate psychological interventions to improve mental health among the young public during the pandemic. The study findings can be used to prepare psychological interventions to improvemental health among the young public during the COVID-19 epidemic. keywords: covid-19; health; outbreak; preprint; stress cache: cord-322229-a7sz6e3c.txt plain text: cord-322229-a7sz6e3c.txt item: #63 of 79 id: cord-324840-ug5a9wx6 author: De Pascale, Gennaro title: The Role of Mannose-Binding Lectin in Severe Sepsis and Septic Shock date: 2013-10-02 words: 5197 flesch: 30 summary: The results indicated that lower MBL levels during fetal inflammatory response syndrome (FIRS) were associated with higher risk of sepsis development independently from gestational age and birth weight Compared with healthy subjects, MBL deficient patients were at increased risk of sepsis, with a significant higher mortality rate in presence of levels below 1000 ng/mL (47.2% versus 22.2%, = 0.05). keywords: deficiency; gene; infections; lectin; levels; mannose; mbl; patients; role; sepsis; shock cache: cord-324840-ug5a9wx6.txt plain text: cord-324840-ug5a9wx6.txt item: #64 of 79 id: cord-325170-50oy9qqy author: Bai, Xiang title: Predicting COVID-19 malignant progression with AI techniques date: 2020-03-23 words: 3049 flesch: 47 summary: Second, the quantitative information of CT data is not detailed enough. Dynamic data is a series of quantitative chest CT data collected at different times. keywords: data; medrxiv; patients; preprint; progression cache: cord-325170-50oy9qqy.txt plain text: cord-325170-50oy9qqy.txt item: #65 of 79 id: cord-328384-jzfr2t3p author: Mudatsir, Mudatsir title: Predictors of COVID-19 severity: a systematic review and meta-analysis date: 2020-09-09 words: 4577 flesch: 37 summary: Furthermore, pulmonary embolism and deep vein thrombosis were also observed in patients with severe COVID-19 73, 74 , which suggests that D-dimer might play a prominent role in governing the severity of COVID-19 patients. Publisher Full Text Pathological findings of COVID-19 associated with acute respiratory distress syndrome The Clinical Manifestations and Chest Computed Tomography Findings of Coronavirus Disease 2019 (COVID-19) Patients in China: A Proportion Meta-Analysis Laboratory findings of COVID-19: a systematic review and meta-analysis Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis PubMed Abstract | Publisher Full Text | Free Full Text COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States Predictors of COVID-19 severity: a systematic review and meta-analysis. keywords: analysis; covid-19; data; disease; levels; meta; patients; review; risk; studies; study cache: cord-328384-jzfr2t3p.txt plain text: cord-328384-jzfr2t3p.txt item: #66 of 79 id: cord-331519-ye4dtna5 author: Garibaldi, B. T. title: Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region date: 2020-05-26 words: 4523 flesch: 51 summary: Conclusions: A combination of demographic and clinical features on admission is strongly associated with progression to severe disease or death in a US cohort of COVID-19 patients. An elevated D-dimer is associated with increased risk of death in COVID-19 patients independent of documented thromboembolic disease, but could also indicate an increased risk of thrombosis. keywords: author; covid-19; death; disease; funder; medrxiv; patients; peer; preprint; review cache: cord-331519-ye4dtna5.txt plain text: cord-331519-ye4dtna5.txt item: #67 of 79 id: cord-332298-ig1j5z07 author: Couetil, Laurent title: Equine Asthma: Current Understanding and Future Directions date: 2020-07-30 words: 15567 flesch: 30 summary: -reported coughing and nasal discharge are associated with clinical findings, arterial oxygen tension, mucus score and bronchoprovocation in horses with recurrent airway obstruction in a field setting Physiological measurements and prevalence of lower airway diseases in trotters with dorsal displacement of the soft palate The occurrence of dynamic structural disorders in the pharynx and larynx, at rest and during exercise, in horses diagnosed with mild and moderate equine asthma (inflammatory airway disease) Indeed, 19 years ago, Robinson et al. found that even in horses with historical severe EA, clinical score failed to reflect low-grade airway obstruction, and suggested that without easily used, field-accessible testing equipment, lower airway disease would go underdiagnosed (53) . keywords: airway; analysis; asthma; bal; cells; cytology; development; diagnosis; disease; equine; field; function; group; horses; human; inflammation; inflammatory; lung; mucus; obstruction; performance; racing; recurrent; research; signs; studies; study; tracheal cache: cord-332298-ig1j5z07.txt plain text: cord-332298-ig1j5z07.txt item: #68 of 79 id: cord-332480-3uodkrkp author: Bonam, Srinivasa Reddy title: Adjunct immunotherapies for the management of severely ill COVID-19 patients date: 2020-04-30 words: 5451 flesch: 35 summary: 12, 13 Plasma obtained from COVID-19 patients, in particular moribund patients, demonstrated increased concentrations of various inflammation-related cytokines and chemokines implicated in the recruitment of immune cells including interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-2, IL-6, IL-7, IL-8, IL-9, IL-17, granulocyte-colony stimulating factor (G-CSF), granulocytemacrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, C-X-C motif chemokine 10 (CXCL10), chemokine ligand 2 (CCL2), CCL3 and CCL4. 1, 14, 15 In addition, COVID-19 patients showed relatively increased neutrophil counts in the blood. keywords: antibody; cells; cov-2; covid-19; disease; patients; plasma; sars; syndrome; therapy; treatment; viral cache: cord-332480-3uodkrkp.txt plain text: cord-332480-3uodkrkp.txt item: #69 of 79 id: cord-334564-bqh9jkds author: Raony, Ícaro title: Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health date: 2020-05-27 words: 9908 flesch: 27 summary: Furthermore, higher serum levels of pro-inflammatory cytokines (e.g., IL-6 and IFN-γ) and chemokines were found in SARS patients with severe disease, as compared to individuals with uncomplicated SARS (44) (45) (46) . Therefore, it is possible that the increased levels of IL-6 are related to the cognitive impairments observed in SARS patients. keywords: axis; cov-2; covid-19; cytokines; health; immune; infection; isolation; levels; patients; sars; stress; studies; symptoms cache: cord-334564-bqh9jkds.txt plain text: cord-334564-bqh9jkds.txt item: #70 of 79 id: cord-334735-up81jotp author: Gillissen, Adrian title: Das schwere akute Atemwegssyndrom (SARS) date: 2003 words: 1300 flesch: 48 summary: Preliminary clinical description of severe acute respiratory syndrome Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong Identification of a novel coronavirus in patients with severe acute respiratory syndrome Infectious diseases: deferring competition, global nets closes on SARS Early therapy with neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment Guideline on management of severe acute respiratory syndrome (SARS) Efficacy and safety of zanamivir in patients with influenza -impact of age, severity of infections and specific risk factors SARS-associated coronavirus A novel coronavirus associated with severe acute respiratory syndrome A major outbreak of severe acute respiratory syndrome in Hong Kong Textbook of influenza SARS: imaging of severe acute respiratory syndrome The use of corticosteroids in SARS Coronavirus as possible cause of severe acute respiratory syndrome Identification of severe acute respiratory syndrome in Canada Comparative fulllength genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection A cluster of cases of severe acute respiratory syndrome in Hong Kong Antivirale Therapie und Prophylaxe der Influenza Severe acute respiratory syndrome (SARS): infection control eine Proteinaseninhibition die Ausbreitung des Virus im [8] Coronavirus main proteinase (3CL pro ) structure: basis of design of anti-SARS drugs Beijing doctor alleges SARS cases cover up in China Centers of Disease Control. keywords: bei; cases; coronavirus; der; disease; sars; syndrome; und cache: cord-334735-up81jotp.txt plain text: cord-334735-up81jotp.txt item: #71 of 79 id: cord-335061-wn8u7u9y author: Zheng, Yichao title: A Learning-based Model to Evaluate Hospitalization Priority in COVID-19 Pandemics date: 2020-08-03 words: 3473 flesch: 43 summary: This model is found effective to identify severe COVID-19 cases on admission, with a sensitivity of 84.6%, a specificity of 84.6%, and an accuracy of 100% to predict the disease progression toward rapid deterioration. The definition of these evaluation metrics 89.2% in discriminating severe COVID-19 cases from their non-severe counterparts 122 (Table 3) . keywords: cases; covid-19; disease; model; patients; study; table; variables cache: cord-335061-wn8u7u9y.txt plain text: cord-335061-wn8u7u9y.txt item: #72 of 79 id: cord-337137-0ey40gzw author: Lo, Anthony WI title: How the SARS coronavirus causes disease: host or organism? date: 2005-12-17 words: 5203 flesch: 40 summary: CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells DC-SIGN: escape mechanism for pathogens Molecular epidemiology of SARS -from Amoy Gardens to Taiwan Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China The Genome sequence of the SARSassociated coronavirus Characterization of a novel coronavirus associated with severe acute respiratory syndrome A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis Characterization of a unique group-specific protein (U122) of the severe acute respiratory syndrome coronavirus Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients The 3a protein of severe acute respiratory syndromeassociated coronavirus induces apoptosis in Vero E6 cells The severe acute respiratory syndrome coronavirus 3a is a novel structural protein Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway The pulmonary physician in critical care * Here, we review the pathology of SARS infection. keywords: acute; cells; coronavirus; cov; disease; infection; lung; patients; proteins; sars; syndrome cache: cord-337137-0ey40gzw.txt plain text: cord-337137-0ey40gzw.txt item: #73 of 79 id: cord-337599-dyxfsojh author: Ahamad, Shakir title: Primed for Global Coronavirus Pandemic: Emerging Research and Clinical Outcome date: 2020-09-19 words: 1996 flesch: 18 summary: Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat 1093 Hospitalized Patients with Severe COVID-19 Pneumonia Effective treatment of severe COVID-19 patients with 1098 tocilizumab Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled 1108 add-on clinical trial First Clinical Use of Lenzilumab to Neutralize GM-CSF in 1113 Patients with Severe COVID-19 Pneumonia A Novel Protein Drug, Novaferon, 1118 as the Potential Antiviral Drug for COVID-19 aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with 1121 Severe Respiratory Complications Following FDA Acceptance of IND Application aTyr-Pharma-Announces-Phase-2-Study-of-1124 ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications Following-FDA-Acceptance-of-IND-Application.html Demand for dexamethasone surges as RECOVERY trial 1037 publishes preprint World first coronavirus treatment approved for NHS use by government Coronavirus | Government approves use of dexamethasone BerGenBio starts bemcentinib dosing in ACCORD Trial Major COVID-19 drugs trial begins in Namilumab and Infliximab selected for CATALYST trial in UK Vidofludimus calcium, a next 1055 generation DHODH inhibitor for the Treatment of relapsing-remitting multiple 1056 sclerosis Receives First Regulatory Approval from German Health Authority 1059 BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor german-health-authority-bfarm-to-initiate-a-phase-2-clinical-trial-of-its-selective-oral-1063 dhodh-inhibitor-imu-838-in-covid-19-patients Germany's BfArM approves Covid-19 trial by Immunic Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical 1068 Trial of IMU-838 in COVID-19 Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT) keywords: coronavirus; covid-19; drug; patients; sars; treatment; trial cache: cord-337599-dyxfsojh.txt plain text: cord-337599-dyxfsojh.txt item: #74 of 79 id: cord-339266-glmshsh6 author: Yin, R. title: Clinical characteristics of 106 patients with neurological diseases and co-morbid coronavirus disease 2019: a retrospective study date: 2020-05-05 words: 4584 flesch: 48 summary: [1] [2] [3] From December 2019 to 15 April 2020, the number of COVID-19 patients worldwide reached 2 million, and the mortality has exceeded 120,000. Novel Coronavirus (2019-nCoV) Situation Report-22 COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients First case of 2019 Novel Coronavirus Disease with Encephalitis A New Symptom of COVID-19: keywords: covid-19; diseases; group; license; patients; preprint; study cache: cord-339266-glmshsh6.txt plain text: cord-339266-glmshsh6.txt item: #75 of 79 id: cord-345371-pjbviagq author: Lisi, Lucia title: Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2 date: 2020-07-23 words: 10674 flesch: 18 summary: Among them, the international Solidarity trial launched by the WHO on March 2020 with the aim to find an effective treatment for COVID-19 patients by comparing four different treatments (i.e., lopinavir/ritonavir, lopinavir/ritonavir plus interferon-β, chloroquine/hydroxychloroquine or remdesivir) against standard of care (see also sections 2 and 3). Besides exerting potential direct antiviral effects, baricitinib might prevent the dysregulated production of pro-inflammatory cytokines typically observed in COVID-19 patients via the inactivation of interleukin-6 (IL6)-JAK-signal transducer and activator of transcription (STAT) pathway (this activity will be more deeply discussed in section 3, especially regarding the JAK inhibitor ruxolitinib). keywords: acute; cells; coronavirus; cov-2; covid-19; covid-19 patients; disease; hydroxychloroquine; infection; interferon; patients; pneumonia; protein; remdesivir; ritonavir; rna; sars; study; syndrome; tocilizumab; treatment; use cache: cord-345371-pjbviagq.txt plain text: cord-345371-pjbviagq.txt item: #76 of 79 id: cord-346539-kxnrf5g5 author: Riggioni, Carmen title: A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2 date: 2020-06-14 words: 15806 flesch: 41 summary: All rights reserved hypersensitivity reactions to drugs may occur more often during the pandemic due to the increased use of drugs and drug interactions, which can result in morbilliform rash, erythroderma, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study Presumed Asymptomatic Carrier Transmission of COVID-19 Eleven faces of coronavirus disease 2019 The proximal origin of SARS-CoV-2 Phylogenetic network analysis of SARS-CoV-2 genomes Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in various human tissues and immune cells in health and disease SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes The potential danger of suboptimal antibody responses in COVID-19 Resistance to coronavirus infection in amino peptidase N-deficient pigs Mammalian Glutamyl Aminopeptidase Genes (ENPEP) and Proteins: Comparative Studies of a Major Contributor to Arterial Hypertension Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 ACE1 polymorphism and progression of SARS Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance Antibody responses to SARS-CoV-2 in patients with COVID-19 Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients The Multifaceted B Cell Response in Allergen Immunotherapy COVID-19 Autopsies EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity Lung eosinophils-A novel virus sink that is defective in asthma? On the other hand, a retrospective study on SARS patients in Hong Kong suggested a better survival rate in patients treated with prednisolone for milder pneumonia or methylprednisolone in more severe cases. keywords: ace2; article; asthma; cases; cells; children; copyright; coronavirus; cov-2; covid-19; covid-19 patients; data; days; disease; figure; human; infection; non; pandemic; patients; reserved; responses; rights; risk; sars; studies; study; transmission; treatment; use cache: cord-346539-kxnrf5g5.txt plain text: cord-346539-kxnrf5g5.txt item: #77 of 79 id: cord-347058-kejcwlng author: Akbari, Hamed title: The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis date: 2020-07-29 words: 3258 flesch: 32 summary: SAA, another important factor capable of improving inflammatory response through activation of chemokine and induction of chemotaxis even at a very low concentration [53] , was found to have elevated circulating levels in severe patients and both were significantly related to COVID-J o u r n a l P r e -p r o o f apoptotic factor The exhaustion of CD8+ T cells in severe patients J o u r n a l P r e -p r o o f may reduce their cellular immune response to SARS-CoV-2. keywords: cases; characteristics; clinical; coronavirus; covid-19; disease; patients; studies; study cache: cord-347058-kejcwlng.txt plain text: cord-347058-kejcwlng.txt item: #78 of 79 id: cord-349558-vof63qat author: Jain, Vageesh title: Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection date: 2020-03-16 words: 4506 flesch: 47 summary: Figure 2 illustrates the proportion of included studies which met each individual appraisal indicator. The clinical spectrum of COVID−19 disease is varied, and identifying factors associated with severe disease has been described as an urgent research priority. keywords: comorbidities; disease; icu; medrxiv; preprint; studies; symptoms cache: cord-349558-vof63qat.txt plain text: cord-349558-vof63qat.txt item: #79 of 79 id: cord-350492-1s6wtj25 author: Ruscitti, Piero title: Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm date: 2020-05-28 words: 3732 flesch: 17 summary: Interestingly, severe COVID-19 is characterized by fever, hyperferritinemia, and a hyper-inflammatory process with a massive release of pro-inflammatory cytokines, which may be responsible for the high rate of mortality. The latter is the result of overwhelming systemic inflammation with a massive release of pro-inflammatory cytokines, quickly progressing to multiple organ dysfunction syndrome and eventually to death (23) . keywords: activation; covid-19; cytokine; disease; ferritin; hlh; hyperferritinemia; patients; syndrome cache: cord-350492-1s6wtj25.txt plain text: cord-350492-1s6wtj25.txt